Generic Drug Names Ending in "-ab"
Drugs ending in "-ab" are monoclonal antibodies, a class of biologic medications used to treat various conditions including autoimmune diseases, cancers, and inflammatory disorders.
Understanding the "-ab" Nomenclature
The suffix "-ab" is part of the International Nonproprietary Name (INN) system established by the World Health Organization to identify monoclonal antibody therapeutics 1, 2. This naming convention uses specific stems to convey information about the drug's structure and origin.
Classification by Antibody Type
Monoclonal antibodies are further categorized by substems that appear before the "-mab" suffix 2:
- -ximab: Chimeric antibodies (e.g., infliximab, rituximab)
- -zumab: Humanized antibodies (e.g., trastuzumab, bevacizumab)
- -umab: Fully human antibodies (e.g., adalimumab, panitumumab)
- -mumab: Fully mouse antibodies (rarely used clinically)
Common Examples from Clinical Practice
Based on FDA-approved biologics for inflammatory diseases 3:
TNF Inhibitors
- Infliximab (Remicade)
- Adalimumab (Humira)
- Certolizumab (Cimzia)
IL-17 Inhibitors
- Secukinumab (Cosentyx)
- Ixekizumab (Taltz)
- Brodalumab (Siliq)
IL-23 Inhibitors
- Guselkumab (Tremfya)
- Tildrakizumab (Ilumya)
- Ustekinumab (Stelara) - targets both IL-12 and IL-23
Biosimilar Naming Convention
The FDA now requires biosimilar versions of monoclonal antibodies to include a four-letter suffix after the core "-mab" name to ensure traceability and pharmacovigilance 4. Examples include:
- Adalimumab-adbm
- Adalimumab-atto
- Infliximab-abda
- Infliximab-dyyb
This naming system allows distinction between the original biologic (bio-originator) and its biosimilar versions while maintaining the recognizable "-mab" core.
Clinical Significance
These medications represent a major therapeutic class with significant impact on morbidity and mortality in conditions like rheumatoid arthritis, psoriasis, inflammatory bowel disease, and various malignancies. The standardized nomenclature facilitates clear communication among healthcare providers, reduces medication errors, and supports effective post-marketing surveillance 4, 5.